Clinical Trials Logo

Filter by:
NCT ID: NCT04807829 Withdrawn - Suicidal Ideation Clinical Trials

Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

Start date: April 2021
Phase: Phase 2
Study type: Interventional

Suicide is a major crisis worldwide with rates projected to continue to increase. There is currently a dearth of novel pharmacologic treatment options for suicide available on the market. The endocannabinoid system has been recently shown to be associated with mood disorders including suicidality. The aim of the study is to determine whether treatment with Nabilone is capable of reducing suicidal ideation in adults after 3 days.

NCT ID: NCT04803630 Withdrawn - Clinical trials for Malignant Solid Neoplasm

Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study

Start date: May 6, 2021
Phase: Early Phase 1
Study type: Interventional

This early phase I trial evaluates the effect of thermal therapy on depression with or without sleep disturbance in cancer survivors. Thermal therapy may help improve quality of life, physical capacity, fatigue, and enhance positive mood and sleep quality. The purpose of this study is to evaluate the potential of thermal therapy to improve patient's quality of life by reducing symptoms of depression, sleep disruption, fatigue and anxiety in cancer survivors.

NCT ID: NCT04802005 Withdrawn - Obesity Clinical Trials

Effects of a Short-term Aerobic Interval Exercise Program on Cardiac Fat and Function in Women With Obesity: A Pilot Study

Start date: March 16, 2021
Phase: N/A
Study type: Interventional

The overall goal of this project is to the study the effects of an aerobic interval training program on cardiac fat, and its relationship to cardiac function using cardiac Magnetic Resonance Imaging.

NCT ID: NCT04801810 Withdrawn - Clinical trials for Overweight and Obesity

Daily Low Oxygen Exposure and Weight Status

LOWS
Start date: May 2022
Phase: N/A
Study type: Interventional

The objective of this single-blind, parallel-arm, randomized clinical trial is to evaluate changes in body weight and composition, assess determinants of energy balance, and measure modulators of energy intake and expenditure, following 8 wk of calorie restriction (CR, -500 kcal/d) in combination with either overnight exposure (8 h/night) to normobaric hypoxia (NH; 15% oxygen, ~8500 ft elevation) or normoxia (NN; 21% oxygen, sea level), using a commercially available, in-home tent system, in adults who are overweight or obese.

NCT ID: NCT04797468 Withdrawn - Clinical trials for Advanced Solid Tumor

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective in participants with advanced solid cancer.

NCT ID: NCT04795960 Withdrawn - Crohn Disease Clinical Trials

Microbiome Modification to Enhance Stelara Response in Crohn's Disease

MIM-TESRIC
Start date: March 18, 2021
Phase: N/A
Study type: Interventional

This pilot study is being completed to determine whether a low-serine diet vs a high serine diet will reduce inflammation and symptoms in Crohn's disease (CD), as well as determine whether a low-serine diet (vs. a high serine diet) will improve responses in patients initiating therapy with Ustekinumab (Stelara), an FDA-approved biologic therapy for Crohn's disease.

NCT ID: NCT04795869 Withdrawn - Clinical trials for Refractory Angioimmunoblastic T-Cell Lymphoma

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back (recurrent). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug that stimulates body's natural antitumor immune responses. Giving brentuximab vedotin together with pembrolizumab may work better than brentuximab vedotin alone in treating patients with recurrent peripheral T-cell lymphoma.

NCT ID: NCT04794790 Withdrawn - Clinical trials for Opioid Dependence Fentanyl

Buprenorphine Induction for Fentanyl Dependent Opioid Users

Start date: May 9, 2022
Phase: Early Phase 1
Study type: Interventional

The overall goal of this pilot study is to characterize illicit fentanyl and combination fentanyl and opioid dependence explicitly, by assessing physiologic barriers to effective buprenorphine induction. Results from this pilot study may make a case for a larger feasibility study to be conducted through the Clinical Trials Network at the National Institutes of Drug Abuse. The primary hypothesis is that individuals dependent on illicit fentanyl and combination fentanyl and opioids will have difficulty with standard buprenorphine induction, and will need a modified approach. The primary outcome measure will be retention on buprenorphine at seven days post induction. The secondary outcome measures will be objective precipitated withdrawal and the rate of patients requiring or requesting to initiate methadone due to intolerance of buprenorphine.

NCT ID: NCT04794335 Withdrawn - Clinical trials for Inflammatory Bowel Diseases

Visceral Afferents

Start date: November 1, 2023
Phase:
Study type: Observational

The vast majority of what is known about the extrinsic innervation of the visceral was obtained through the study of preclinical models, primarily rats and mice. Given a growing list of important species differences, the investigators wish to determine the extent to which what scientists think they know about the control of visceral afferent excitability learned through the study of rodents holds true for humans. The investigators wish to establish an ex-vivo preparation using intestine surgically removed for the treatment of cancer, ischemia, etc, that would normally be disposed of as medical waste, to study the properties of the extrinsic innervation of the intestine. Tissue will be recovered in the OR, taken back to the lab, and evoked activity in the neurons innervating the intestine will be studied with extracellular recording techniques. Pharmacological approaches will be used to characterize the ion channels/receptors controlling the excitability of visceral afferents. After recording, tissue may be further analyzed with biochemical approaches such as western blot, PCR, and/or flow cytometry.

NCT ID: NCT04794205 Withdrawn - Beta-Caryophyllene Clinical Trials

Acute Changes In Thermal Pain Response Following Single Oral Dose of Beta-Cary

BCP-Pain
Start date: September 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Beta-Caryophyllene is an essential oil and cannabis plant derivative also found in edible herbs. It has shown promise as a potential analgesic in preclinical trials. However, there are no human studies characterizing pharmacokinetics of BCP in humans. Therefore, it is of great importance to determine the pharmacokinetics of BCP in humans so that appropriate dosing can be developed for analgesia. This pharmacokinetic work will lay the groundwork for subsequent experiments testing the neural mechanism of BCP on pain.